超1亿融资！创新生物电子起搏器

Core Viewpoint - Ceryx Medical has successfully completed a $15 million funding round to advance the clinical research and miniaturization of its core product, the Cysoni bioelectronic pacemaker, which aims to address chronic heart failure by simulating natural heart rhythms [1][2]. Funding and Recognition - The recent $15 million financing is a critical part of Ceryx's three funding rounds, with previous rounds including £575,000 in seed funding in 2020 and £3.8 million in 2022 [2][5]. - Ceryx has received various accolades for its technological innovations, including the "Business Startup Award" from the Institute of Physics in the UK, and has collaborated with industry leader Osypka Medical for clinical validation [3]. Market Environment and Application Potential - Chronic heart failure (CHF) affects approximately 30 million patients globally and leads to over 1 million hospitalizations annually in Europe and the US, consuming more than 2% of national healthcare budgets [4]. - Despite existing treatments like CRT and ICD, nearly 50% of CHF patients face a mortality risk within five years of diagnosis, highlighting the need for improved therapeutic options [4]. Core Technology - Ceryx's Cysoni system aims to synchronize heart and respiratory rhythms, offering a novel intervention path that complements existing treatments [10]. - The technology is adaptable and could potentially be applied to other conditions such as hypertension, arrhythmias, and spinal cord injuries [10][13]. Clinical Progress - The Cysoni system has received approval from the UK MHRA in 2024 and is currently in the RSA-pace study phase, which evaluates its safety and efficacy in postoperative patients [15]. - A permanent implantable version, Cysoni-XT, is in development, with plans for broader clinical studies starting in 2025-2026 [15]. - Ceryx is also collaborating with Hydrix to develop a portable clinical trial system to enhance early human research efficiency [15]. Company Overview - Ceryx Medical was founded in 2016 and is based in Cardiff, UK, with a team that includes experts in artificial neurons and cardiac neurophysiology [16].